TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31915058

Group type: EXPERIMENTAL
Intervention: Medical management
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty and stenting
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Intracranial and extra‐cranial bypass
Number of subjects: 66

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 66
Study: 31462629

Group type: EXPERIMENTAL
Intervention: 100% orange juice with 5 g of enzyme-treated orange pomace fiber (OPF)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 100% orange juice (OJ)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both OPF juice and OJ
Number of subjects: 10
Study: 28815987

Group type: EXPERIMENTAL
Intervention: Lorcaserin plus diet and exercise
Number of subjects: 5624

Group type: EXPERIMENTAL
Intervention: Lorcaserin
Number of subjects: 5624

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5624
Study: 25598270

Group type: EXPERIMENTAL
Intervention: Dietary folate equivalent
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Folic acid (FA)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Folic acid (FA) in individuals with CC genotype for MTHFR C677T variant
Number of subjects: 141
Study: 24638046

Group type: EXPERIMENTAL
Intervention: Bupropion-SR plus escitalopram
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Venlafaxine-XR plus mirtazapine
Number of subjects: 567

Group type: COMPARATOR
Intervention: Escitalopram plus placebo
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Combination treatments
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 567
Study: 22971486

Group type: COMPARATOR
Intervention: Percutaneous approach
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Paraspinal approach
Number of subjects: 61

Group type: COMPARATOR
Intervention: Both approaches
Number of subjects: 61
Study: 19778774

Group type: EXPERIMENTAL
Intervention: Paclitaxel‐eluting stent (PES)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bare‐metal stent (BMS)
Number of subjects: 80
Study: 18080228

Group type: EXPERIMENTAL
Intervention: Topical or systemic corticosteroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leukotriene receptor antagonists (montelukast)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-5 blockers (Mepolizumab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bougies or balloon dilation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anti-inflammatory agents
Number of subjects: 0
Study: 15046934

Group type: EXPERIMENTAL
Intervention: Index TKA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Revision TKA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 12653168

Group type: EXPERIMENTAL
Intervention: Dried hazelnut (1 mg to 1 g hazelnut protein)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo doses
Number of subjects: 31
Study: 9520230

Group type: EXPERIMENTAL
Intervention: Pain site measurement
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control site measurement
Number of subjects: 28

Group type: COMPARATOR
Intervention: Examiner's knowledge manipulation
Number of subjects: 28
Study: 7927488

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 200 micrograms nasal spray twice daily for 6 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 48
Study: 2582771

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 75 micrograms gestodene
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oral administration of 25 micrograms gestodene
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oral administration of 75 micrograms gestodene
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oral administration of 125 micrograms gestodene
Number of subjects: 6
Study: 31489425

Group type: EXPERIMENTAL
Intervention: Quality control circle guided nursing
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine nursing
Number of subjects: 120
Study: 28161559

Group type: EXPERIMENTAL
Intervention: Commentary exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Live commentary production
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commentary unexposed group
Number of subjects: 0
Study: 26482128

Group type: EXPERIMENTAL
Intervention: Systematic rapid screen-and-treat program using a point-of-care analysis with molecular quantification method
Number of subjects: 6800

Group type: COMPARATOR
Intervention: Usual care management
Number of subjects: 6800

Group type: EXPERIMENTAL
Intervention: Systematic rapid screen-and-treat program
Number of subjects: 6800
Study: 23603887

Group type: EXPERIMENTAL
Intervention: Gabapentin (600 mg) plus dexamethasone (4 mg IV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus dexamethasone (4 mg IV)
Number of subjects: 0
Study: 21908768

Group type: EXPERIMENTAL
Intervention: Three doses of HPV16/18 vaccine (Cervarix)
Number of subjects: 5967

Group type: EXPERIMENTAL
Intervention: Two doses of HPV16/18 vaccine (Cervarix)
Number of subjects: 5967

Group type: EXPERIMENTAL
Intervention: One dose of HPV16/18 vaccine (Cervarix)
Number of subjects: 5967
Study: 19552598

Group type: EXPERIMENTAL
Intervention: Xuezhikang (1200 mg/d)
Number of subjects: 55
Study: 17349072

Group type: EXPERIMENTAL
Intervention: Conjugated equine oestrogen (CEE; 0.625 mg/d)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 15367255

Group type: EXPERIMENTAL
Intervention: SF‐6D
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: HUI3
Number of subjects: 331

Group type: COMPARATOR
Intervention: Both measures
Number of subjects: 331
Study: 11808063

Group type: EXPERIMENTAL
Intervention: 25% aqueous extract of freshly prepared miswak solution
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Soaking in miswak extract
Number of subjects: 12
Study: 9670874

Group type: EXPERIMENTAL
Intervention: The Knack (pelvic muscle precontraction)
Number of subjects: 27
Study: 7846263

Group type: EXPERIMENTAL
Intervention: Chemotherapy with radiotherapy to the primary tumor and CNS
Number of subjects: 57

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 57
Study: 2899090

Group type: COMPARATOR
Intervention: Insulin alone (22 mU/m2.min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Insulin with SRIH (250 micrograms/h) and glucagon (0.4 ng/kg.min)
Number of subjects: 12
Study: 30523464

Group type: EXPERIMENTAL
Intervention: Accelerated Ponseti technique (cast change interval of 3 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Ponseti technique (cast change interval of 7 days)
Number of subjects: 0
Study: 28190980

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (0.03 g.kg.d‐1 during 14 d)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 24990422

Group type: EXPERIMENTAL
Intervention: Systolic BP variability (measured as coefficient of variability)
Number of subjects: 2501

Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 2501

Group type: EXPERIMENTAL
Intervention: Inclusion for cerebrovascular disease
Number of subjects: 2501

Group type: EXPERIMENTAL
Intervention: Logistic regression model with BP variability
Number of subjects: 2501
Study: 22496276

Group type: COMPARATOR
Intervention: Hypocaloric, normoproteic Mediterranean diet (MeD)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Hypocaloric, normoproteic Mediterranean diet plus periodized moderate-to-high intensity training (MeDE)
Number of subjects: 45
Study: 21736762

Group type: EXPERIMENTAL
Intervention: Usual care plus educational materials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Usual care plus educational materials and social worker intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care by nephrologists
Number of subjects: 0
Study: 17270519

Group type: EXPERIMENTAL
Intervention: Microprocessor control prosthetic knee (Otto Bock C-Leg)
Number of subjects: 21
Study: 16276705

Group type: EXPERIMENTAL
Intervention: Nebulized albuterol (Group A)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Nebulized furosemide (Group B)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Combination of nebulized albuterol and furosemide (Group C)
Number of subjects: 59
Study: 12045535

Group type: EXPERIMENTAL
Intervention: Erythropoietin (600 U/kg) weekly for 3 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no erythropoietin)
Number of subjects: 29
Study: 9928551

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8577886

Group type: EXPERIMENTAL
Intervention: d‐amphetamine (5, 10 mg/70 kg, BID)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: d‐amphetamine (30 mg/70 kg in four doses)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 2243148

Group type: EXPERIMENTAL
Intervention: 30 mg nifedipine
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 60 mg nifedipine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 946844

Group type: EXPERIMENTAL
Intervention: HPV‐77 DE‐5
Number of subjects: 5153

Group type: EXPERIMENTAL
Intervention: HPV‐77 DK‐12
Number of subjects: 5153

Group type: EXPERIMENTAL
Intervention: Cendehill
Number of subjects: 5153

Group type: EXPERIMENTAL
Intervention: All vaccines
Number of subjects: 5153
Study: 29667330

Group type: EXPERIMENTAL
Intervention: TNF inhibitors (TNFI)
Number of subjects: 6712

Group type: EXPERIMENTAL
Intervention: Non-TNF inhibitors (non-TNFI)
Number of subjects: 6712

Group type: EXPERIMENTAL
Intervention: Corticosteroids ≥ 5 mg/day
Number of subjects: 6712

Group type: COMPARATOR
Intervention: Non-RA group
Number of subjects: 6712
Study: 25787780

Group type: EXPERIMENTAL
Intervention: Alcohol intake (two glasses of red wine, 12% ethanol)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control day (no alcohol)
Number of subjects: 18
Study: 25111667

Group type: EXPERIMENTAL
Intervention: Nebulized combination of salbutamol 1.875 mg/0.5 mL and ipratropium bromide 0.375 mg/0.5 mL
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 22401327

Group type: EXPERIMENTAL
Intervention: Insulin-induced lipid suppression
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of Intralipid
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Common prediction model using a maximum of 10 gases
Number of subjects: 23
Study: 20429383

Group type: EXPERIMENTAL
Intervention: Carbon dioxide laser tonsillectomy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Routine method (control group)
Number of subjects: 102
Study: 18729835

Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moexipril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 0
Study: 15856409

Group type: EXPERIMENTAL
Intervention: SJW (Esbericum capsules; 240 mg/die of extract, 3.5 mg hyperforin)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 14585254

Group type: EXPERIMENTAL
Intervention: Closed-Loop Stimulation (CLS)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: DDD+ overdrive pacing
Number of subjects: 149

Group type: COMPARATOR
Intervention: DDDR pacing
Number of subjects: 149
Study: 11104879

Group type: EXPERIMENTAL
Intervention: Angio-Seal device
Number of subjects: 150

Group type: COMPARATOR
Intervention: FemoStop device
Number of subjects: 150
Study: 8967858

Group type: EXPERIMENTAL
Intervention: Nucleolar organizer (NO) activity in high-grade malignancy lymphomas
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Nucleolar organizer (NO) activity in low-grade malignancy lymphomas
Number of subjects: 51

Group type: COMPARATOR
Intervention: Nucleolar organizer (NO) activity in reactive follicular hyperplasia
Number of subjects: 51
Study: 1559951

Group type: EXPERIMENTAL
Intervention: High-Intensity Low-Volume Taper (HIT)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Low-Intensity Moderate-Volume Taper (LIT)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Rest-Only Taper (ROT)
Number of subjects: 9
Study: 3901772

Group type: EXPERIMENTAL
Intervention: +1.00 D add treatment
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: +2.00 D add treatment
Number of subjects: 213

Group type: COMPARATOR
Intervention: Single vision (standard treatment)
Number of subjects: 213
Study: 29771161

Group type: EXPERIMENTAL
Intervention: Single below-knee cast (n = 10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 3 serial casts (n = 10)
Number of subjects: 20
Study: 29455211

Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone (ITD) administered once weekly for 4 consecutive weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Oral medication
Number of subjects: 37
Study: 26293380

Group type: EXPERIMENTAL
Intervention: Low-dose fludarabine with darbepoetin alfa
Number of subjects: 97

Group type: COMPARATOR
Intervention: Low-dose fludarabine without darbepoetin alfa
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 97

Group type: COMPARATOR
Intervention: Chemoimmunotherapy
Number of subjects: 97
Study: 25239603

Group type: EXPERIMENTAL
Intervention: Trimethobenzamide
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 21566199

Group type: EXPERIMENTAL
Intervention: R1663 (oral factor Xa inhibitor)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 20645031

Group type: EXPERIMENTAL
Intervention: Routine adjunctive manual thrombectomy devices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Larger manual thrombectomy devices (7F) or mechanical devices
Number of subjects: 0
Study: 17403494

Group type: EXPERIMENTAL
Intervention: Parents
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Parents with higher education levels
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Fathers
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Mothers
Number of subjects: 829

Group type: COMPARATOR
Intervention: Parental socioeconomic level
Number of subjects: 829
Study: 16259540

Group type: EXPERIMENTAL
Intervention: Escitalopram (10 or 20 mg/day)
Number of subjects: 371

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 371
Study: 12100180

Group type: EXPERIMENTAL
Intervention: 5% niacinamide moisturizer
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: 2% niacinamide + sunscreen
Number of subjects: 138

Group type: COMPARATOR
Intervention: vehicle moisturizer
Number of subjects: 138

Group type: COMPARATOR
Intervention: sunscreen
Number of subjects: 138
Study: 10492259

Group type: EXPERIMENTAL
Intervention: Salmeterol (42 microg, twice-daily)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 408

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 408
Study: 8619468

Group type: EXPERIMENTAL
Intervention: Totally extraperitoneal laparoscopic approach
Number of subjects: 120
Study: 1793366

Group type: EXPERIMENTAL
Intervention: Auranofin (3 mg twice daily for 12 weeks)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Inactive placebo (3 mg twice daily for 12 weeks)
Number of subjects: 25
Study: 6131066

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 53

Group type: COMPARATOR
Intervention: Lorazepam
Number of subjects: 53
Study: 30682835

Group type: EXPERIMENTAL
Intervention: High GI diet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low GI diet
Number of subjects: 12
Study: 29194205

Group type: EXPERIMENTAL
Intervention: Protective eye shield (mask)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No mask
Number of subjects: 36
Study: 27155547

Group type: EXPERIMENTAL
Intervention: Chest Compression Fraction (CCF) during resuscitation
Number of subjects: 1997

Group type: EXPERIMENTAL
Intervention: Increasing Chest Compression Fraction (CCF)
Number of subjects: 1997
Study: 24103444

Group type: EXPERIMENTAL
Intervention: Specialist geriatric medical management
Number of subjects: 433

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 433
Study: 22073842

Group type: EXPERIMENTAL
Intervention: Higher-intensity peritoneal dialysis (prescribed Kt/V of 0.8 per session)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Lower-intensity peritoneal dialysis (prescribed Kt/V of 0.5 per session)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Higher-intensity peritoneal dialysis (prescribed Kt/V of 0.8)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Lower-intensity peritoneal dialysis (prescribed Kt/V of 0.5)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both groups after 4 PD sessions
Number of subjects: 61
Study: 19844115

Group type: EXPERIMENTAL
Intervention: Diet (balanced hypocaloric diet, weekly meetings with dietician)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Exercise (90 min moderate exercise 3 days/week)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Diet + Exercise (balanced hypocaloric diet + 90 min moderate exercise 3 days/week)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 162

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Diet + Exercise
Number of subjects: 162
Study: 17220958

Group type: EXPERIMENTAL
Intervention: Gene therapy strategies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Advanced-phase studies
Number of subjects: 0
Study: 15545857

Group type: EXPERIMENTAL
Intervention: Pneumovax II
Number of subjects: 113

Group type: COMPARATOR
Intervention: Mengivax A&C
Number of subjects: 113
Study: 10718384

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Band ligation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synchronous combination of band ligation and sclerotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metachronous approach using sclerotherapy after band ligation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histoacryl
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Balloon-occluded retrograde transvenous obliteration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TIPS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound for Doppler studies
Number of subjects: 0
Study: 9293051

Group type: EXPERIMENTAL
Intervention: clarithromycin suspension (7.5 mg/kg twice daily)
Number of subjects: 229

Group type: COMPARATOR
Intervention: amoxycillin syrup (125 mg/kg three times daily for body weight < 25 kg, or 250 mg/kg three times daily for body weight 25 kg)
Number of subjects: 229
Study: 8112371

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Felodipine ER 10 mg
Number of subjects: 12
Study: 3571860

Group type: EXPERIMENTAL
Intervention: Geriatric clinic care for 18 months
Number of subjects: 205

Group type: COMPARATOR
Intervention: Traditional Veterans Administration care
Number of subjects: 205
Study: 29199070

Group type: EXPERIMENTAL
Intervention: 4% articaine (Ar4)
Number of subjects: 72

Group type: COMPARATOR
Intervention: 2% mepivacaine (Me2)
Number of subjects: 72
Study: 27196663

Group type: EXPERIMENTAL
Intervention: Project AIM (Adult Identity Mentoring) intervention, details on dosage and duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified, details on intervention not available.
Number of subjects: 0
Study: 24053794

Group type: EXPERIMENTAL
Intervention: Continuous bipolar plasma vaporisation of the prostate (C‐BPVP)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Standard bipolar vaporisation (S‐BPVP)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Monopolar transurethral resection of the prostate (TURP)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: C‐BPVP and S‐BPVP
Number of subjects: 180

Group type: COMPARATOR
Intervention: C‐BPVP, S‐BPVP, and TURP
Number of subjects: 180
Study: 22464673

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with allergen tablets over a 4-month period
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 79
Study: 20973922

Group type: EXPERIMENTAL
Intervention: Lixivaptan
Number of subjects: 650

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 650
Study: 18242584

Group type: EXPERIMENTAL
Intervention: Typhoid vaccination
Number of subjects: 16
Study: 19153582

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 4376

Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 4376
Study: 15058795

Group type: EXPERIMENTAL
Intervention: Interferon +/− 13‐cis‐retinoic acid
Number of subjects: 191
Study: 12181464

Group type: EXPERIMENTAL
Intervention: 1% benzalkonium chloride (BC) vaginal suppository and bathing solution
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo vaginal suppository and bathing solution
Number of subjects: 107
Study: 9542564

Group type: EXPERIMENTAL
Intervention: Forced-air surface warming on upper extremities and upper thorax
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oesophageal heat exchanger
Number of subjects: 24

Group type: COMPARATOR
Intervention: No active warming (control group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Comparison of internal group (I and III) vs external group (II)
Number of subjects: 24
Study: 8038233

Group type: EXPERIMENTAL
Intervention: Conventional-dose Ara-C (200 mg/m2 d 1-5) combined with idarubicin (12 mg/m2 d 1-3)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Conventional-dose Ara-C/idarubicin
Number of subjects: 23
Study: 3359906

Group type: EXPERIMENTAL
Intervention: Wedge elevation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Elevation on blocks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Flat position
Number of subjects: 15
Study: 11570630

Group type: EXPERIMENTAL
Intervention: Insulin-like growth factor-I (IGF-I) levels measured in cerebrospinal fluid (CSF)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control participants (11 participants; 6 females, 5 males; mean age 3.8 years)
Number of subjects: 11
Study: 29529897

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) 8 mg/kg/month for 6 months
Number of subjects: 13

Group type: COMPARATOR
Intervention: Conventional therapy (Conv)
Number of subjects: 13
Study: 30104008

Group type: EXPERIMENTAL
Intervention: Local therapies (LT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maintenance chemotherapy (MC)
Number of subjects: 0